TABLE 1.
COMPOSITIONS OF THE PREPARED BATCHES OF OXYBUTYNIN MDTS FORMULATIONS.
| Ingredients (%w/w) | F1 | F2 | F3 | F4 | F5 | F6 | F7 | F8 | F9 | F10 | F11 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oxybutynin | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Glyceryl mono oleate | - | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | - | - |
| Myristyl lactate | - | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | - | - |
| Water | - | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 |
| Cyclomethicone | - | - | - | - | - | - | - | 0.5 | 0.5 | - | - |
| Carbopol-940 | - | - | 0.50 | - | 1.0 | 0.25 | - | - | 0.50 | - | 0.50 |
| Lutrol F-127 | - | 0.10 | - | 0.20 | - | - | 0.05 | 0.10 | - | 0.10 | - |
| Ethanol:acetone:methylal(2:1:2) | q.s. | q.s. | q.s. | q.s. | q.s. | q.s. | q.s. | q.s. | q.s. | q.s. | q.s. |
*Formulation F1 did not contain any film forming agent and was used as a reference. Formulation F2 and F3 were found to be optimized formulations. The effect of increased and decreased concentrations of film forming agents was revealed by formulations F4, F5, F6 and F7. The presence of cyclomethicone as a cosolvent did not affect the film formation from optimized MDTS formulations. Absence of penetration enhancers led to very less drug release as shown by formulations F10 and F11.